Jingnan Liao1, Keli Luo2,3, Dehua Cheng1,2,3, Pingyuan Xie1,2,3, Yueqiu Tan1,2,3, Liang Hu1,2,3, Guangxiu Lu1,2,3, Fei Gong1,2,3, Ge Lin4,5,6. 1. Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha, 410008, China. 2. Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, 410008, China. 3. Reproductive and Genetic Hospital of CITIC-XIANGYA, Changsha, 410008, China. 4. Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha, 410008, China. linggf@hotmail.com. 5. Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, 410008, China. linggf@hotmail.com. 6. Reproductive and Genetic Hospital of CITIC-XIANGYA, Changsha, 410008, China. linggf@hotmail.com.
Abstract
PURPOSE: The purpose of this study is to explore the reproductive outcomes of women with Turner syndrome (TS) in preimplantation genetic testing (PGT) cycles. METHODS: A retrospective study of 100 controlled ovarian stimulating cycles, 68 TS (sixty-four mosaic Turner syndrome (MTS) and four pure Turner syndrome (PTS)) women underwent PGT was conducted from 2013 to 2018. RESULTS: Embryo X chromosome abnormal rates of TS women were significantly higher than women with normal karyotype (7.04 vs 1.61%, P<0.01). Cumulative live birth rates (CLBR) after PGT-NGS treatment were lower in TS than control (31.15 vs 45.59%, P<0.05). Clinical pregnancy rates per transfer (CPR), miscarriage rates (MR) and live birth rates per transfer (LBR) remained comparable between TS and control group. Reproductive outcomes (X chromosome abnormal rates, CPR, MR, LBR and CLBR) among low (<10%), medium (10-50%) and high (>50%) level 45,X mosaicism groups were not statistically different. CONCLUSIONS: To avoid high risk of embryo X chromosome abnormalities, prenatal or preimplantation genetic testing should be recommended to mosaic or pure TS patients.
PURPOSE: The purpose of this study is to explore the reproductive outcomes of women with Turner syndrome (TS) in preimplantation genetic testing (PGT) cycles. METHODS: A retrospective study of 100 controlled ovarian stimulating cycles, 68 TS (sixty-four mosaic Turner syndrome (MTS) and four pure Turner syndrome (PTS)) women underwent PGT was conducted from 2013 to 2018. RESULTS: Embryo X chromosome abnormal rates of TS women were significantly higher than women with normal karyotype (7.04 vs 1.61%, P<0.01). Cumulative live birth rates (CLBR) after PGT-NGS treatment were lower in TS than control (31.15 vs 45.59%, P<0.05). Clinical pregnancy rates per transfer (CPR), miscarriage rates (MR) and live birth rates per transfer (LBR) remained comparable between TS and control group. Reproductive outcomes (X chromosome abnormal rates, CPR, MR, LBR and CLBR) among low (<10%), medium (10-50%) and high (>50%) level 45,X mosaicism groups were not statistically different. CONCLUSIONS: To avoid high risk of embryo X chromosome abnormalities, prenatal or preimplantation genetic testing should be recommended to mosaic or pure TS patients.
Authors: Iris D Noordman; Janiëlle Aem van der Velden; Henri Jlm Timmers; Catherine Pienkowski; Birgit Köhler; Marlies Kempers; Nicole Reisch; Annette Richter-Unruh; Wiebke Arlt; Anna Nordenström; Emma A Webb; Nel Roeleveld; Hedi L Claahsen-van der Grinten Journal: Pediatr Endocrinol Rev Date: 2019-04
Authors: Claus H Gravholt; Niels H Andersen; Gerard S Conway; Olaf M Dekkers; Mitchell E Geffner; Karen O Klein; Angela E Lin; Nelly Mauras; Charmian A Quigley; Karen Rubin; David E Sandberg; Theo C J Sas; Michael Silberbach; Viveca Söderström-Anttila; Kirstine Stochholm; Janielle A van Alfen-van derVelden; Joachim Woelfle; Philippe F Backeljauw Journal: Eur J Endocrinol Date: 2017-09 Impact factor: 6.664
Authors: Anna Hagman; Anne Loft; Ulla-Britt Wennerholm; Anja Pinborg; Christina Bergh; Kristiina Aittomäki; Karl-Gösta Nygren; Liv Bente Romundstad; Johan Hazekamp; Viveca Söderström-Anttila Journal: Hum Reprod Date: 2013-03-27 Impact factor: 6.918